NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis $2.24 -0.04 (-1.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.22%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mereo BioPharma Group Stock (NASDAQ:MREO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mereo BioPharma Group alerts:Sign Up Key Stats Today's Range$2.20▼$2.2950-Day Range$1.76▼$2.6752-Week Range$1.58▼$5.02Volume568,594 shsAverage Volume1.12 million shsMarket Capitalization$356.16 millionP/E RatioN/ADividend YieldN/APrice Target$7.71Consensus RatingBuy Company OverviewMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Read More… Mereo BioPharma Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreMREO MarketRank™: Mereo BioPharma Group scored higher than 38% of companies evaluated by MarketBeat, and ranked 685th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 3 research reports in the past 90 days.Read more about Mereo BioPharma Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mereo BioPharma Group are expected to decrease in the coming year, from ($0.03) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mereo BioPharma Group is -32.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mereo BioPharma Group is -32.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 6.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mereo BioPharma Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.79% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.79% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.23 News SentimentMereo BioPharma Group has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mereo BioPharma Group this week, compared to 2 articles on an average week.Search Interest6 people have searched for MREO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MREO Stock News HeadlinesMereo BioPharma Group (MREO) to Release Earnings on WednesdayMay 19, 2025 | americanbankingnews.comMREO FY2025 EPS Estimate Increased by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 24, 2025 | Paradigm Press (Ad)Leerink Partnrs Issues Negative Outlook for MREO EarningsMay 17, 2025 | americanbankingnews.comWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | finanznachrichten.deMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | globenewswire.comMereo BioPharma Group plc (MREO): A Bull Case TheoryApril 18, 2025 | finance.yahoo.comSee More Headlines MREO Stock Analysis - Frequently Asked Questions How have MREO shares performed this year? Mereo BioPharma Group's stock was trading at $3.50 at the beginning of 2025. Since then, MREO stock has decreased by 36.0% and is now trading at $2.24. View the best growth stocks for 2025 here. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc (NASDAQ:MREO) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. Who are Mereo BioPharma Group's major shareholders? Mereo BioPharma Group's top institutional shareholders include Frazier Life Sciences Management L.P. (4.92%), 683 Capital Management LLC (2.92%), Tejara Capital Ltd (1.59%) and Aberdeen Group plc (1.38%). Insiders that own company stock include Denise Scots-Knight, Charles Sermon, Christine Ann Fox, John A Lewicki, Alexandra Hughes-Wilson and Deepika Pakianathan. View institutional ownership trends. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR). Company Calendar Last Earnings5/13/2025Today5/24/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MREO CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.71 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+244.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual Sales$1 million Price / Sales356.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book6.22Miscellaneous Outstanding Shares159,000,000Free Float148,738,000Market Cap$356.16 million OptionableOptionable Beta0.53 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MREO) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.